HSPA5 and renal carcinoma: As for BiP, it was shown to be up-regulated in several types of cancer, e.g. hepatocellular carcinoma, renal carcinoma, and breast cancer43, and to be involved in cancer pathophysiology by conferring chemoresistance to tumour-associated endothelial cells44.